Related Experiment Video
Updated: Jun 28, 2026
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Routine Urine Drug Screening in Palliative Care-A Call for Evidence Before Implementation
Mellar P Davis1, Katie Fitzgerald Jones2
1Department of Supportive Oncology (M.P.D.), Oncology Palliative Medicine, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, USA.
Journal of Pain and Symptom Management
|June 26, 2026
Summary
Routine urine drug screening (UDS) in palliative care lacks proven patient safety benefits and carries risks. Recommendations should be individualized pending evidence of benefit.
Area of Science:
- Palliative Care
- Pain Management
- Medical Ethics
Background:
- Urine drug screening (UDS) is increasingly used in palliative care for opioid stewardship.
- Evidence supporting routine UDS in palliative populations requires critical evaluation.
Purpose of the Study:
- To assess the evidence for routine UDS in palliative and cancer pain populations.
- Examined safety benefits, cost, ethics, guideline consistency, harms, and racial disparities.
Main Methods:
- Conducted a narrative review and critical analysis using the SANRA framework.
- Searched PubMed/MEDLINE and systematically reviewed clinical practice guidelines (NCCN, ASCO, CDC).
- Included studies on UDT utilization, outcomes, or policy in adult cancer or palliative care patients on opioid therapy.
Main Results:
- No studies show routine UDS improves patient safety outcomes (e.g., overdose prevention, pain control).
- Aberrancy rates (15-54%) reflect surveillance, not safety endpoints; UDS rarely alters opioid management.
- Documented risks include financial toxicity, stigmatization, care termination, and racial disparities.
Conclusions:
- Routine UDS in palliative care lacks demonstrated benefit and has documented harms.
- Recommendations should be individualized, awaiting evidence of patient safety benefit.
- Proposes future research and an equity-informed framework for selective screening.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).